HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is a ubiquitously expressed RNA-binding protein encoded by the HNRNPA1 gene on chromosome 12q13.1 in humans. As a founding member of the hnRNP protein family, HNRNPA1 is one of the most abundant RNA-binding proteins in mammalian cells, comprising approximately 5-10% of total nuclear proteins. The protein consists of 372 amino acids organized into two RNA recognition motifs (RRM1 and RRM2) at its N-terminus, followed by a C-terminal glycine-rich region that facilitates protein-protein interactions. HNRNPA1 exists as part of a dynamic ribonucleoprotein complex that associates with nascent pre-mRNA transcripts, making it a critical regulator of gene expression at multiple levels.
Function/Biology
...
HNRNPA1 Protein
Overview
HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is a ubiquitously expressed RNA-binding protein encoded by the HNRNPA1 gene on chromosome 12q13.1 in humans. As a founding member of the hnRNP protein family, HNRNPA1 is one of the most abundant RNA-binding proteins in mammalian cells, comprising approximately 5-10% of total nuclear proteins. The protein consists of 372 amino acids organized into two RNA recognition motifs (RRM1 and RRM2) at its N-terminus, followed by a C-terminal glycine-rich region that facilitates protein-protein interactions. HNRNPA1 exists as part of a dynamic ribonucleoprotein complex that associates with nascent pre-mRNA transcripts, making it a critical regulator of gene expression at multiple levels.
Function/Biology
HNRNPA1 functions as a pleiotropic regulator of RNA metabolism with multiple cellular roles. In transcriptional regulation, HNRNPA1 associates with nascent RNA polymerase II transcripts and influences both elongation and termination processes. The protein exhibits particularly robust activity in alternative splicing regulation, where it typically promotes exon skipping through competitive binding to RNA sequences, particularly AU-rich elements. HNRNPA1 also participates in mRNA export from the nucleus, serving as a component of the nuclear export machinery. Beyond splicing, HNRNPA1 regulates mRNA stability and localization through interactions with AU-rich elements in 3' untranslated regions. The protein shuttles between nucleus and cytoplasm in a continuously dynamic manner, enabling it to influence both nuclear and cytoplasmic gene expression processes.
neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Role in Neurodegeneration
HNRNPA1 has emerged as a critical factor in neurodegenerative disease pathogenesis through multiple mechanisms. Pathogenic mutations in HNRNPA1 (notably the P239S, D262V, and Q303K variants) have been identified in patients with multisystem proteinopathy (MSP), a progressive neuromuscular disorder characterized by inclusion body myopathy, frontotemporal dementia, and/or Paget disease of bone. These mutations cause aberrant HNRNPA1 aggregation and sequestration into pathological inclusions, a hallmark of proteinopathic disorders similar to those observed in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The sequestration of mutant HNRNPA1 into inclusion bodies depletes functional protein from the nucleoplasm, disrupting normal splicing and mRNA processing. Additionally, wild-type HNRNPA1 can be sequestered into inclusions containing other disease-associated proteins, suggesting a broader pathogenic role in neurodegeneration.
Molecular Mechanisms
The pathogenic mechanism of HNRNPA1 mutations involves both loss-of-function and gain-of-function effects. Mutations in the RNA-binding domains reduce RNA-binding capacity while simultaneously promoting protein misfolding and aggregation through disruption of normal domain architecture. The glycine-rich C-terminal region, which is intrinsically disordered, becomes hyperproned to self-assembly when destabilized by point mutations, leading to formation of amyloid-like fibrillar aggregates. These aggregates sequester not only mutant HNRNPA1 but also wild-type HNRNPA1 and functionally related hnRNPs, creating a pathological domino effect. At the molecular level, sequestration disrupts the normal splicing of critical neuronal transcripts, including those involved in cytoskeletal organization and protein quality control. Additionally, accumulated HNRNPA1 aggregates impair proteasomal function and trigger cellular stress responses, ultimately leading to neuronal dysfunction and death.
Clinical/Research Significance
HNRNPA1 mutations represent a definitive genetic cause of MSP and related proteinopathies, with significant implications for understanding neurodegeneration mechanisms. Research into HNRNPA1 has illuminated fundamental principles of how RNA-binding protein misfolding drives disease, providing a paradigm for understanding ALS and FTD pathogenesis. Therapeutic strategies are being explored, including agents that prevent HNRNPA1 aggregation, enhance clearance of misfolded protein, and restore splicing function of remaining functional protein. Understanding HNRNPA1 biology has also contributed to recognition of the broader hnRNPopathy disease family, expanding the clinical spectrum of RNA-binding protein-associated neurodegeneration.
Related Entities
hnRNPA2/B1 (related RNA-binding protein with MSP mutations)
FUS protein (another aggregation-prone RNA-binding protein in ALS/FTD)
TDP-43 (TAR DNA-binding protein with similar pathogenic mechanisms)